M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced late Thursday that the US Food and Drug Administration has approved updated labels for its two CAR T cell therapies, reducing patient monitoring requirements and removing Risk Evaluation and Mitigation Strategy (REMS) programs....
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search